文献速递肝病

代谢功能障碍相关脂肪性肝病的遗传学:最新进展

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-07-31

本文综述了代谢功能障碍相关脂肪性肝病(MASLD)遗传学研究的最新进展,涵盖全基因组关联研究、全外显子组关联研究、全表型组关联研究及全外显子测序等技术揭示的疾病异质性机制与患者分层前景,并讨论了多基因风险评分、靶向测序的临床可用性、基因-环境交互及基因相关治疗策略。

要点

  • MASLD遗传学研究借助全基因组关联研究、全外显子组关联研究、全表型组关联研究及全外显子测序等技术快速发展。
  • 计算能力提升、基于人工智能的新分析算法及大规模表型良好队列的招募推动了上述进展。
  • 综述讨论了多基因风险评分和靶向测序是否已准备好用于临床,并介绍了基因相关治疗策略。

核心结论

  • MASLD遗传学进展正逐渐揭示疾病异质性的机制,并在患者分层方面显示出有希望的结果。
  • 为全面管理MASLD,进行风险分层很重要,本文介绍了包括极端表型在内的全表型组关联研究关联更新。
  • 本文讨论了已批准药物治疗方法的局限性,并综述了基因相关机制在治疗开发中的潜力,包括对MASLD患者进行基因检测的决策。

研究设计与样本

  • 综述,总结MASLD遗传学研究进展,涵盖全基因组关联研究、全外显子组关联研究、全表型组关联研究及全外显子测序等方法。

主要发现

  • 计算能力提升、包括部分基于人工智能的新分析算法开发以及大规模表型良好队列的招募推动了遗传学研究的进展。
  • 本文介绍了从下一代测序方法中获得的新的生物学见解。
  • 本文讨论了发现MASLD新遗传位点(包括罕见变异)的创新方法。

关键数值与推荐

  • 本文介绍了包括极端表型在内的全表型组关联研究关联的更新。
  • 本文讨论了多基因风险评分和靶向测序是否已准备好用于临床。
  • 本文以精准医学为特别关注点,介绍了遗传与环境在通过生活方式或标准治疗调节遗传风险中的相互作用等概念。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in the genetics of metabolic dysfunction-associated steatotic liver disease (MASLD) are gradually revealing the mechanisms underlying the heterogeneity of the disease and have shown promising results in patient stratification. Genetic characterization of the disease has been rapidly developed using genome-wide association studies, exome-wide association studies, phenome-wide association studies, and whole exome sequencing. These advances have been powered by the increase in computational power, the development of new analytical algorithms, including some based on artificial intelligence, and the recruitment of large and well-phenotyped cohorts. This review presents an update on genetic studies that emphasize new biological insights from next-generation sequencing approaches. Additionally, we discuss innovative methods for discovering new genetic loci for MASLD, including rare variants. To comprehensively manage MASLD, it is important to stratify risks. Therefore, we present an update on phenome-wide association study associations, including extreme phenotypes. Additionally, we discuss whether polygenic risk scores and targeted sequencing are ready for clinical use. With particular focus on precision medicine, we introduce concepts such as the interplay between genetics and the environment in modulating genetic risk with lifestyle or standard therapies. A special chapter is dedicated to gene-based therapeutics. The limitations of approved pharmacological approaches are discussed, and the potential of gene-related mechanisms in therapeutic development is reviewed, including the decision to perform genetic testing in patients with MASLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sookoian S, Rotman Y, Valenti L, et al. Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update. Clin Gastroenterol Hepatol. 2024. PMID: 39094912. doi:10.1016/j.cgh.2024.05.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。